Skip to main content
PEPG
NASDAQ Life Sciences

PepGen Prices $125M Offering at $5.00, a Discount to Tuesday's Close

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$5.349
Mkt Cap
$364.305M
52W Low
$1.31
52W High
$7.8
52W Position info
308% above low
Off High info
31% below high
Rel. Volume info
5.7× avg
Market data snapshot near publication time

PEPG has more than doubled off its 52-week low of $1.31 on elevated volume (5.7× avg).

Summary

PepGen priced its $125M public offering at $5.00 a share for 25 million shares, roughly 6.5% below the $5.3485 last price — a modest discount that suggests the deal got done but without aggressive demand. Underwriting discounts and commissions are $0.30 per share, $7,500,000 total, leaving proceeds before expenses of $4.70 per share, $117,500,000 total, and estimated net proceeds of approximately $116.9 million, or approximately $134.5 million if the option is exercised in full; offering expenses other than those discounts are estimated at approximately $600,000, and the company will reimburse underwriters up to $15,000 for their FINRA counsel fee. The raise follows Monday's positive FREEDOM2-DM1 topline data (46.5% mean splicing correction at 10 mg/kg) and the offering launch that same evening; the company ended Q3 with $104.8M in cash and securities, guided to fund operations into 2028. Underwriters have a 30-day option on up to 3.75 million more shares, which would bring the initial public offering price to $143,750,000, underwriting discounts and commissions to $8,625,000 and proceeds before expenses to $135,125,000. Common stock outstanding immediately after the offering is 94,261,055 shares, or 98,011,055 shares if the option is exercised in full, with immediate dilution of $2.67 per share to investors and as adjusted net tangible book value of $220.0 million, or $2.33 per share, an increase of $0.84 per share to existing stockholders; if the option is exercised in full, as adjusted net tangible book value is $2.42 per share, the increase in net tangible book value is $0.93 per share and immediate dilution is $2.58 per share. The dilution is meaningful for a company of this size, but the cash extends the runway well past the 12.5 mg/kg data readout for the lead DM1 program, which remains on U.S. partial clinical hold. Closing is expected on or about November 13, 2026.

Updated with an SEC 424B5 filing · What changed

Updates

  1. · SEC 424B5 — PepGen's 25M-share offering at $5.00 yields $117.5M net proceeds before expenses, with a 30-day option for 3.75M more shares and closing expected November 13, 2026.

    • Underwriting Terms — Underwriting discounts and commissions are $0.30 per share, $7,500,000 total, leaving proceeds before expenses of $4.70 per share, $117,500,000 total. Dealers get a concession not in excess of $0.18 per share; with the option, discounts are $8,625,000 and proceeds before expenses $135,125,000.
    • Net Proceeds and Expenses — Estimated net proceeds are approximately $116.9 million, or approximately $134.5 million if the option is exercised in full. Other offering expenses are estimated at approximately $600,000, and underwriters are reimbursed up to $15,000 for their FINRA counsel fee.
    • Lock-Up — The company, executive officers and directors agreed not to sell or transfer common stock or convertible securities for 60 days after the underwriting agreement date without written consent of Leerink Partners and Stifel.
    • Capitalization and Dilution — Common stock outstanding immediately after the offering is 94,261,055 shares, or 98,011,055 shares if the option is exercised in full. Immediate dilution is $2.67 per share; as adjusted net tangible book value is $220.0 million, or $2.33 per share, an increase of $0.84 per share to existing stockholders.
    • Underwriter Allocations
      • Underwriter share allocations: Leerink Partners LLC 11,250,000; Stifel, Nicolaus & Company, Incorporated 5,750,000; Guggenheim Securities, LLC 5,250,000; Oppenheimer & Co. Inc. 2,250,000; H.C. Wainwright & Co., LLC 500,000.
      • Joint bookrunning managers: Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC; passive bookrunner Oppenheimer & Co. Inc.; lead manager H.C. Wainwright & Co., LLC.
    All 13 details
    • Underwriting discounts and commissions $0.30 per share, $7,500,000 total; proceeds before expenses $4.70 per share, $117,500,000 total.
    • Net proceeds estimated approximately $116.9 million, or approximately $134.5 million if the option to purchase additional shares is exercised in full.
    • Offering expenses payable by the company, other than underwriting discounts and commissions, estimated at approximately $600,000.
    • Company agreed to reimburse underwriters up to $15,000 for their FINRA counsel fee, deemed underwriting compensation under FINRA Rule 5110.
    • Company, executive officers and directors agreed not to sell or transfer common stock or convertible securities for 60 days after the underwriting agreement date without written consent of Leerink Partners and Stifel.
    • Common stock outstanding immediately after offering: 94,261,055 shares, or 98,011,055 shares if the underwriters exercise their option in full.
    • Immediate dilution of $2.67 per share to investors; as adjusted net tangible book value $220.0 million, or $2.33 per share; increase of $0.84 per share to existing stockholders.
    • Underwriter share allocations: Leerink Partners LLC 11,250,000; Stifel, Nicolaus & Company, Incorporated 5,750,000; Guggenheim Securities, LLC 5,250,000; Oppenheimer & Co. Inc. 2,250,000; H.C. Wainwright & Co., LLC 500,000.
    • Underwriters propose to offer shares to dealers at the public offering price less a concession not in excess of $0.18 per share.
    • Joint bookrunning managers: Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC; passive bookrunner Oppenheimer & Co. Inc.; lead manager H.C. Wainwright & Co., LLC.
    • Prospectus supplement covers 25,000,000 shares of common stock.
    • With option: initial public offering price $143,750,000; underwriting discounts and commissions $8,625,000; proceeds, before expenses, to us $135,125,000.
    • If option exercised in full: as adjusted net tangible book value $2.42 per share; increase in net tangible book value $0.93 per share; immediate dilution $2.58 per share.

At the time of this announcement, PEPG was trading at $5.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $364.3M. The 52-week trading range was $1.31 to $7.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

PEPG - Latest Insights

PEPG
Nov 10, 2026, 4:23 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $4.89
Real-time Price: $5.04 info
Change: +$0.155 (+3%) info
Market Cap: $349.077M info
PEPG
Nov 10, 2026, 7:05 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $5.04 info
Change: +$2.64 (+110%) info
Market Cap: $349.077M info
PEPG
Nov 10, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $5.04 info
Change: +$2.64 (+110%) info
Market Cap: $349.077M info
PEPG
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $5.04 info
Change: +$2.24 (+80%) info
Market Cap: $349.077M info
PEPG
Aug 06, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.10
Real-time Price: $5.04 info
Change: +$2.94 (+140%) info
Market Cap: $349.077M info